These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 1634900)

  • 1. Myasthenogenicity in the main immunogenic region of acetylcholine receptor as modified by conformational design: an approach to antigenic synthetic peptides.
    Takamori M; Hamada T; Okumura S
    J Neurol Sci; 1992 Jun; 109(2):182-7. PubMed ID: 1634900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conformational modification enhances myasthenogenicity in synthetic peptide of acetylcholine receptor alpha-subunit.
    Takamori M; Okumura S; Komai K; Satake R
    J Neurol Sci; 1990 Nov; 99(2-3):219-27. PubMed ID: 2086725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Myasthenia gravis: pathogenesis and therapeutic approach on the basis of molecular structure and immunogenicity of acetylcholine receptor].
    Takamori M
    Nihon Rinsho; 1994 Nov; 52(11):3038-45. PubMed ID: 7996707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specificity of the T cell immune response to acetylcholine receptor in experimental autoimmune myasthenia gravis. Response to subunits and synthetic peptides.
    Fujii Y; Lindstrom J
    J Immunol; 1988 Mar; 140(6):1830-7. PubMed ID: 2450133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural characterization of the main immunogenic region of the Torpedo acetylcholine receptor.
    Morell SW; Trinh VB; Gudipati E; Friend A; Page NA; Agius MA; Richman DP; Fairclough RH
    Mol Immunol; 2014 Mar; 58(1):116-31. PubMed ID: 24333757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myasthenogenic significance of synthetic alpha-subunit peptide 183-200 of Torpedo californica and human acetylcholine receptor.
    Takamori M; Okumura S; Nagata M; Yoshikawa H
    J Neurol Sci; 1988 Jun; 85(2):121-9. PubMed ID: 3260271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Precise epitope mapping of monoclonal antibodies to the cytoplasmic side of the acetylcholine receptor alpha subunit. Dissecting a potentially myasthenogenic epitope.
    Tzartos SJ; Remoundos MS
    Eur J Biochem; 1992 Aug; 207(3):915-22. PubMed ID: 1379917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of complementary peptides and their antibodies in B-cell-mediated autoimmune disease: prevention of experimental autoimmune myasthenia gravis with a peptide vaccine.
    Araga S; Blalock JE
    Immunomethods; 1994 Oct; 5(2):130-5. PubMed ID: 7874437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. beta-Bungarotoxin binding protein is immunogenic but lacks myasthenogenicity in rats.
    Qiao J; Wang ZY; Link H
    J Neurol Sci; 1994 Feb; 121(2):190-3. PubMed ID: 8158214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of amino acids critical to the main immunogenic region of intact acetylcholine receptors by in vitro mutagenesis.
    Saedi MS; Anand R; Conroy WG; Lindstrom J
    FEBS Lett; 1990 Jul; 267(1):55-9. PubMed ID: 2365090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis, and characterization of a 39 amino acid peptide mimic of the main immunogenic region of the Torpedo acetylcholine receptor.
    Trinh VB; Foster AJ; Fairclough RH
    Mol Immunol; 2014 May; 59(1):79-90. PubMed ID: 24491490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Main immunogenic region of Torpedo electroplax and human muscle acetylcholine receptor: localization and microheterogeneity revealed by the use of synthetic peptides.
    Tzartos SJ; Loutrari HV; Tang F; Kokla A; Walgrave SL; Milius RP; Conti-Tronconi BM
    J Neurochem; 1990 Jan; 54(1):51-61. PubMed ID: 1688377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors that determine the severity of experimental myasthenia gravis.
    Drachman DB; McIntosh KR; Yang B
    Ann N Y Acad Sci; 1998 May; 841():262-82. PubMed ID: 9668247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of experimental autoimmune myasthenia gravis by manipulation of the immune network with a complementary peptide for the acetylcholine receptor.
    Araga S; LeBoeuf RD; Blalock JE
    Proc Natl Acad Sci U S A; 1993 Sep; 90(18):8747-51. PubMed ID: 8378359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoadsorption in myasthenia gravis based on specific ligands mimicking the immunogenic sites of the acetylcholine receptor.
    Takamori M; Maruta T
    Ther Apher; 2001 Oct; 5(5):340-50. PubMed ID: 11778918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Region of peptide 125-147 of acetylcholine receptor alpha subunit is exposed at neuromuscular junction and induces experimental autoimmune myasthenia gravis, T-cell immunity, and modulating autoantibodies.
    Lennon VA; McCormick DJ; Lambert EH; Griesmann GE; Atassi MZ
    Proc Natl Acad Sci U S A; 1985 Dec; 82(24):8805-9. PubMed ID: 3878521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope.
    Atassi MZ; Oshima M; Deitiker P
    Crit Rev Immunol; 2001; 21(1-3):1-27. PubMed ID: 11642597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of experimental autoimmune myasthenia gravis by a monoclonal antibody to a complementary peptide for the main immunogenic region of the acetylcholine receptors.
    Araga S; Galin FS; Kishimoto M; Adachi A; Blalock JB
    J Immunol; 1996 Jul; 157(1):386-92. PubMed ID: 8683141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Torpedo-mouse hybrid acetylcholine receptors reveals immunodominance of the alpha subunit in myasthenia gravis antisera.
    Loutrari H; Tzartos SJ; Claudio T
    Eur J Immunol; 1992 Nov; 22(11):2949-56. PubMed ID: 1385157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence against acetylcholine receptor having a main immunogenic region as target for autoantibodies in myasthenia gravis.
    Lennon VA; Griesmann GE
    Neurology; 1989 Aug; 39(8):1069-76. PubMed ID: 2474772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.